StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)

Close on Nov 18, 2026Market cap $103.35MP/E –Yield –

Cellectis operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cellectis's operating income for the twelve months ending Dec 31, 2023 was -$97.30M. For fiscal 2025 it was -$33.08M. The highest annual figure on record is -$6.97M in fiscal 2014.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$33.08M–
FY2024Dec 31, 2024-$59.55M–
FY2023Dec 31, 2023-$97.30M–
FY2022Dec 31, 2022-$89.67M–
FY2021Dec 31, 2021-$103.48M–
FY2020Dec 31, 2020-$42.31M–
FY2019Dec 31, 2019-$123.55M–
FY2018Dec 31, 2018-$105.09M–
FY2017Dec 31, 2017-$92.65M–
FY2016Dec 31, 2016-$67.30M–
FY2015Dec 31, 2015-$30.98M–
FY2014Dec 31, 2014-$6.97M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.52M–
Q2 FY2025Jun 30, 2025-$9.59M–
Q2 FY2024Jun 30, 2024-$17.21M–
Q4 FY2023Dec 31, 2023-$29.58M–
Q3 FY2023Sep 30, 2023-$20.67M–
Q2 FY2023Jun 30, 2023-$23.62M–
Q2 FY2022Jun 30, 2022-$27.31M–
Q2 FY2021Jun 30, 2021-$37.48M–
Q2 FY2020Jun 30, 2020-$33.03M–
Q2 FY2019Jun 30, 2019-$35.13M–

More Cellectis figures

See a number that looks wrong?